Search Results for “EC” – Page 141 – media

Health-Tech Startup Suki’s Voice Assistant Device for Doctors bags $20million

Suki, a California-based, health-tech startup founded by former Flipkart executive in 2017 is said to have raised a new round of capital of $15 million.
- Source: Ddu
- 697
- May 8, 2018
AI digital health Market Views
Healthcare sector startups to watch in 2018

Lately, Biotech and immunotherapy have been widely covered by media, but there’s more to healthcare than taking leaps of faith on new tech. New companies are addressing administrative functions, personalized medicine, and proactive wellness in their approach to the health industry.
- Source: Crunchbase
- 804
- May 7, 2018
healthcare Market Views
Harvard’s Wyss Institute partners with Cellectis to recode the human genome

Recode project will use Cellectis’ TALEN gene editing technology to create first virus-resistant human cells for manufacturing therapeutics and developing new cell-based therapies
- Source: immunotherapies
- 645
- May 4, 2018
CAR T-cells Cellectis immunotherapies Market Views
Casetabs receives investment of $6 million from Nueterra Capital for surgery coordination app

California-based Casetabs, the pioneer of cloud-based surgery coordination technology, yesterday announced it has received $6 million in series A-funding to scale its surgery coordination application.
- Source: MobiHealthNews
- 759
- May 3, 2018
Company Insights digital health mHealth
Tisagenlecleucel Granted FDA Approval for Large B-Cell Lymphoma

Based on data from the phase II JULIET study, tisagenlecleucel (Kymriah) has received FDA approval for the treatment of adult patients with relapsed/refractory large B-cell lymphoma—including diffuse large B-cell lymphoma (DLBCL), high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma—after 2 or more lines of systemic therapy.
- Source: targetedonc
- 3,679
- May 3, 2018
FDA New Approvals tisagenlecleucel
Gilead inks $90m deal with Verily to create “molecular map” of inflammatory disease

Gilead Sciences (NSDQ:GILD) is reportedly slated to pay Alphabet’s Verily Life Sciences $90 million over three years to analyze cells from patients with rheumatoid arthritis, inflammatory bowel disease and lupus-related diseases.
- Source: drugdeliverybusiness
- 628
- May 2, 2018
Gilead Market Views rheumatoid arthritis
7 Side Effects Of Hormonal Birth Control Nobody Told You About

To be clear, this doesn't mean you are likely to experience these side effects after going on birth control. But if you do notice any of them after you start, there could be a connection there, and it's worth talking to your doctor if you don't like the effects you're experiencing or notice anything out of the ordinary. Here are a few possible side effects of hormonal birth control that you may not have been told about.
- Source: drugdu
- 436
- April 30, 2018
Hormonal Birth Control side effects
Multiple sclerosis drug could reduce painful side effects of common cancer treatment

Researchers from the Saint Louis University School of Medicine have discovered why many multiple myeloma patients experience severe pain when treated with the anticancer drug bortezomib. The study, which will be published April 27 in the Journal of Experimental Medicine, suggests that a drug already approved to treat multiple sclerosis could mitigate this effect, allowing myeloma patients to successfully complete their treatment and relieving the pain of myeloma survivors.
- Source: medicalxpress.
- 455
- April 28, 2018
multiple myeloma Researches
GSK reports Q1 sales decline

GlaxoSmithKline has booked a 2 percent dip in revenues for the first quarter to £7.2 billion, after results were hit by a “significant currency impact” and lower sales of prescription drugs. Profit after tax fell 38 percent to £759 million, while earnings per share dropped to 11.2p from 21.4p a year ago.
- Source: pharmatimes
- 491
- April 28, 2018
Company Insights GSK
Specialty Vaccines for Overlooked Infectious Diseases–Challenges and Opportunities

Developing specialty vaccines for emerging and overlooked infectious diseases is a challenging and rewarding enterprise with specific opportunities and problems. Large companies have not historically prioritized this area and instead have focused on the development and commercialization of routine vaccines and vaccines for diseases with more significant global markets.
- Source: fiercepharma
- 475
- April 28, 2018
Researches vaccines

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.